Study of the Anti-tumoral Immune Response
NCT02854644 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 167
Last updated 2022-06-01
Summary
This study evaluates the frequency of the spontaneous T cells specific CD4 answers of tumoral antigens breast cancer and glioma.
Conditions
Interventions
- OTHER
-
additional blood sample
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Besancon
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-01-27
- Primary Completion
- 2021-10-27
- Completion
- 2021-10-27
Countries
- France
Study Locations
More Related Trials
-
Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma
NCT00576641 ·Status: COMPLETED ·Phase: PHASE1
-
Dendritic Cell Vaccination for Patients with Solid Tumors
NCT01291420 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Breast Cancer
NCT03113019 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy
NCT03548571 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines
NCT02840123 ·Status: UNKNOWN ·Phase: PHASE1
-
Deciphering Mechanisms Underlying Cancer Immunogenicity
NCT03958240 ·Status: RECRUITING ·Phase: NA
-
Safety and Efficacy of γδ T Cell Against Gastric Cancer
NCT02585908 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
NCT00001582 ·Status: COMPLETED
-
Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors
NCT04765462 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Immunity to Infection in Healthy Participants and Participants With Cancer
NCT05787964 ·Status: ACTIVE_NOT_RECRUITING
-
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
NCT04523688 ·Status: RECRUITING ·Phase: PHASE2
-
Tumor-specific T Cells in Lung Cancer
NCT02515760 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Immune Repertoire of Ovarian HGSC
NCT03794115 ·Status: UNKNOWN
-
Biological Therapy in Treating Patients With Advanced Cancer
NCT00005956 ·Status: COMPLETED ·Phase: NA
-
Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer
NCT06131775 ·Status: RECRUITING ·Phase: NA
-
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
NCT05292859 ·Status: COMPLETED
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
Dendritic Cell Based Therapy of Metastatic Breast Cancer
NCT00197925 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
NCT05976906 ·Status: UNKNOWN ·Phase: PHASE1
-
T Cell Response in Hypersensitivity Syndrome
NCT00213447 ·Status: COMPLETED
-
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
NCT01875653 ·Status: TERMINATED ·Phase: PHASE3
-
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
NCT00576537 ·Status: COMPLETED ·Phase: PHASE2
-
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
NCT00243594 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells
NCT04105582 ·Status: COMPLETED ·Phase: PHASE1
-
Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma
NCT00846456 ·Status: COMPLETED ·Phase: PHASE1/PHASE2